| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9149565 | Physiology & Behavior | 2005 | 14 Pages |
Abstract
It can be concluded that GSA is an important neurotoxin. As GSA is increased in patients with uremia, it probably contributes to their neurological symptoms. Knowledge of neurotoxic effects and mechanisms of action of GSA and other uremic retention solutes could help in the development of more efficient treatment of uremic patients. Animal models like the 'GSA mouse model' are useful tools for research in this context.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Physiology
Authors
An Torremans, Bart Marescau, Debby Van Dam, Chris Van Ginneken, Frans Van Meir, Pierre-Paul Van Bogaert, Rudi D'Hooge, Jan de Vente, Peter Paul De Deyn,